Do platelet function analyzer-100 testing results correlate with bleeding events after percutaneous renal biopsy?

Area of Science:

• Nephrology
• Hematology
• Diagnostic Medicine

Background:

• Predicting bleeding risk after percutaneous kidney biopsy (PKB) remains challenging.
• The utility of the Platelet Function Analyzer-100 (PFA-100) in this context is unexamined.

Purpose of the Study:

• To prospectively evaluate the association between PFA-100 closure times and post-biopsy bleeding complications.
• To determine if PFA-100 collagen/epinephrine (CEPI) and collagen/adenosine diphosphate (CADP) tests can predict hematoma, hematuria, or the need for packed red blood cell (PRBC) transfusions after PKB.

Main Methods:

• A prospective study involving 56 participants undergoing PKB under ultrasound guidance.
• Collected data included PFA-100 CEPI and CADP closure times, patient demographics, clinical parameters, and biopsy characteristics.
• Outcomes assessed were hematoma formation, hematuria, and PRBC transfusion requirements.

Main Results:

• PFA-100 CEPI was abnormal in 8.93% and PFA-CADP in 14.3% of participants.
• Bleeding events (hematoma, hematuria) were observed in 19% and 8.9% of participants, respectively; 7% required PRBC transfusions.
• Neither PFA-100 CEPI nor CADP closure times correlated with any bleeding complications. PRBC transfusions were associated with elevated BUN, creatinine, and increased biopsy passes.

Conclusions:

• PFA-100 testing does not appear to improve patient care for routine PKB.
• Current PFA-100 assays are unlikely to add value in predicting bleeding risk post-PKB.